Scpharmaceuticals Inc (NASDAQ:SCPH) has received a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price objective of $12.67 for the company and are expecting that the company will post ($0.50) EPS for the current quarter, according to Zacks. Zacks has also assigned Scpharmaceuticals an industry rank of 85 out of 255 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised shares of Scpharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Friday, August 17th.

A number of hedge funds have recently made changes to their positions in SCPH. BlackRock Inc. lifted its holdings in Scpharmaceuticals by 21,048.8% during the 1st quarter. BlackRock Inc. now owns 288,469 shares of the company’s stock valued at $3,577,000 after purchasing an additional 287,105 shares during the last quarter. Northern Trust Corp bought a new position in Scpharmaceuticals during the 1st quarter valued at about $595,000. Acadian Asset Management LLC bought a new position in Scpharmaceuticals during the 2nd quarter valued at about $169,000. Colony Group LLC bought a new position in Scpharmaceuticals during the 2nd quarter valued at about $131,000. Finally, Schwab Charles Investment Management Inc. bought a new position in Scpharmaceuticals during the 1st quarter valued at about $167,000. 43.59% of the stock is owned by hedge funds and other institutional investors.

NASDAQ SCPH traded down $0.14 during midday trading on Friday, hitting $3.91. The company had a trading volume of 16,337 shares, compared to its average volume of 30,462. The company has a debt-to-equity ratio of 0.10, a quick ratio of 13.80 and a current ratio of 13.80. Scpharmaceuticals has a fifty-two week low of $3.88 and a fifty-two week high of $18.17.

Scpharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.04. Research analysts predict that Scpharmaceuticals will post -2.09 EPS for the current year.

Scpharmaceuticals Company Profile

scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.

Read More: Asset Allocation, Balancing Your Investments

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.